A Significant Achievement in the Treatment of CMC1 Osteoarthritis
KeriMedical is proud to announce that TOUCH® CMC 1 Prosthesis has officially received FDA Premarket Approval (PMA), marking a significant achievement in the treatment of CMC1 osteoarthritis. This approval recognizes our innovative product for meeting the highest standards of safety and efficacy in the U.S. healthcare market.
A New Solution for CMC1 Osteoarthritis Treatment
With FDA approval, TOUCH® is now available for use in the United States as a leading solution for CMC1 osteoarthritis treatment. This approval offers healthcare professionals a new option for treating patients suffering from thumb carpometacarpal osteoarthritis. The prosthesis is designed to improve patients’ quality of life by restoring thumb function and alleviating pain.
The Benefits of TOUCH® CMC 1 Prosthesis
The approval of TOUCH® CMC 1 Prosthesis is not just a major achievement for KeriMedical but also a breakthrough for patients in the U.S. With FDA clearance, patients are likely to experience significant improvements in:
- Pain relief
- Increased functionality
- Overall quality of life
TOUCH® provides an innovative solution that enables better thumb mobility, helping patients return to their daily activities with less pain and greater ease.
A Milestone in U.S. CMC 1 Arthroplasty Surgery
This FDA approval marks an important step forward for CMC 1 arthroplasty surgery in the U.S. TOUCH® is the first total prosthesis with dual mobility available in the U.S., offering a new level of stability and flexibility for patients undergoing thumb joint replacement surgery.
Acknowledgments
At KeriMedical, we are extremely proud of this achievement and would like to take a moment to thank our dedicated team, clinical partners, and all those involved in making this innovative solution a reality. Your unwavering commitment and hard work have made this success possible.
As we continue to celebrate this momentous approval, we look forward to working closely with healthcare professionals and patients in the U.S. to offer the highest level of care and support. Stay tuned for more updates and information about TOUCH® and other upcoming innovations.
